Carcinoma renale
Dr. Aldo Chioni
ASL Toscana Sud Est U.O.C. Oncologia Medica
Grosseto
Supernovae in Oncologia
Pisa 19-20 settembre 2019
Nel 2018
Novità 2019
Baseline Characteristics
Overall Survival
Overall Survival in Key Subgroups
Progression-Free Survival
Progression-Free Survival in Key Subgroups<br />
Confirmed Objective Response Rate
Treatment-Related Adverse Events: <br />Incidence ≥20%
Pembrolizumab plus Axitinib as First-Line Therapy for mRCC: Outcomes in the Combined IMDC Intermediate/Poor Risk and Sarcomatoid Subgroups of KEYNOTE-426
IMDC Favorable Risk: OS, PFS, and ORR
Response: Presence of Sarcomatoid Featuresa
PFS: Presence of Sarcomatoid Featuresa
Biomarker analyses from JAVELIN Renal 101: avelumab + axitinib vs sunitinib <br />in advanced renal cell carcinoma
Biomarker assessments and methodology
PFS according to PD-L1 IHC
Slide 9
Slide 12
Slide 13
PFS according to expression of select genes
Slide 17
Slide 19